(Q37224303)

19 August 2017

1 reference

title

Gene-expression profiling in epithelial ovarian cancer (English)

1 reference

19 August 2017

1 reference

Panagiotis A Konstantinopoulos

series ordinal

1

1 reference

19 August 2017

Dimitrios Spentzos

series ordinal

2

1 reference

19 August 2017

Stephen A Cannistra

series ordinal

3

1 reference

19 August 2017

publication date

22 July 2008

1 reference

Nature Clinical Practice Oncology

19 August 2017

published in

1 reference

19 August 2017

volume

5

1 reference

19 August 2017

issue

10

1 reference

19 August 2017

page(s)

577-587

1 reference

Identification of genes involved in resistance to interferon-alpha in cutaneous T-cell lymphoma

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

Diverse tumorigenic pathways in ovarian serous carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

21 January 2018

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPONC1178

1 reference

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Genome-wide views of cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Microarray expression technology: from start to finish

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Roadmap for developing and validating therapeutically relevant genomic classifiers

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Extracting biology from high-dimensional biological data

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

DNA microarrays in clinical oncology

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Concordance among gene-expression-based predictors for breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Gene expression patterns that characterize advanced stage serous ovarian cancers

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Gene expression signature with independent prognostic significance in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Microarray analysis and tumor classification

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Molecular profiling of platinum resistant ovarian cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Unique gene expression profile based on pathologic response in epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Linking oncogenic pathways with therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Oncogenic pathway signatures in human cancers as a guide to targeted therapies

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Genomic signatures to guide the use of chemotherapeutics.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Tumor necrosis factor-alpha related gene response to Epothilone B in ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Characterisation of molecular events following cisplatin treatment of two curable ovarian cancer models: contrasting role for p53 induction and apoptosis in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Biology of epithelial ovarian cancer: implications for screening women at high genetic risk

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Osteopontin as a potential diagnostic biomarker for ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Overexpression of kallikrein 10 in epithelial ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Targeted therapy for metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Minimum information about a microarray experiment (MIAME)-toward standards for microarray data

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Activation of the p21(Waf1/Cip1) promoter by the ets oncogene family transcription factor E1AF.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

The human XRCC9 gene corrects chromosomal instability and mutagen sensitivities in CHO UV40 cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Antiproliferative effect of beta-elemene in chemoresistant ovarian carcinoma cells is mediated through arrest of the cell cycle at the G2-M phase

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Cross-resistance to death ligand-induced apoptosis in cisplatin-selected HeLa cells associated with overexpression of DDB2 and subsequent induction of cFLIP.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

A role for polymerase eta in the cellular tolerance to cisplatin-induced damage

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Bak and Bax are non-redundant during infection- and DNA damage-induced apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Luteolin sensitizes the anticancer effect of cisplatin via c-Jun NH2-terminal kinase-mediated p53 phosphorylation and stabilization.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

A novel cinnamic acid derivative that inhibits Cdc25 dual-specificity phosphatase activity.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

The cell cycle inhibitor p57(Kip2) promotes cell death via the mitochondrial apoptotic pathway.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Anticancer and chemosensitizing effects of 2,3-DCPE in ovarian carcinoma cell lines: link with ERK activation and modulation of p21WAF1/CIP1, Bcl-2 and Bcl-xL expression

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embryonal carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Identification by functional cloning from a retroviral cDNA library of cDNAs for ribosomal protein L36 and the 10-kDa heat shock protein that confer cisplatin resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Microsomal glutathione transferase 1 in anticancer drug resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1178

7 January 2021

Identifiers

DOI

10.1038/NCPONC1178

1 reference

19 August 2017

1 reference